Europe Psychedelic Drugs Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Europe Psychedelic Drugs Market Analysis

Psychedelic drugs involve various types of chemical substances including lysergic acid diethylamide (LSD) and chemical extracted from plants. These drugs have the ability to change or enhance the sensory perceptions, thought processes, energy levels and have also been reported to facilitate spiritual experiences.

Psychedelic Drugs Market Insights

The psychedelic drugs can be categorized into empathogens and dissociative drugs (such as phenylcyclohexyl piperidine (PCP)) and serotonergic (classic hallucinogens) such as LSD. Both types of psychedelic drugs can cause hallucinations and feeling of sensation, moreover, dissociative drugs can make a person to fell out of control from their body or environment and makes them feel disconnected. Based on the source, psychedelic drugs have been categorized under natural and synthetic types.

These drugs have wide applications in the treatment of major depressive disorder, post-traumatic stress disorder, panic disorder, treatment-resistant depression and opiate addiction among others. Psychedelic drugs are also known by several other names such as lysergic acid derivative (LSD) which are also known as blotter, dots, sugar, acid, trips and window pane, ketamine are also known as vitamin K, bump, green, K/special K, purple and super acid, PCP are also known as angel/angel dust, boat/love boat, peace, killer weed, super grass and ozone.

Europe Psychedelic Drugs Market Size

Europe psychedelic drugs market size was valued at USD 337.40 million in 2024 and is projected to reach USD 878.09 million by 2032, with a CAGR of 12.7% during the forecast period of 2025 to 2032.

Report Scope and Market Segmentation       

Psychedelic Drugs Market Definition

Psychedelic drugs involve various types of chemical substances including lysergic acid diethylamide (LSD) and chemical extracted from plants. These drugs have the ability to change or enhance the sensory perceptions, thought processes, energy levels and have also been reported to facilitate spiritual experiences.

The psychedelic drugs can be categorized into empathogens and dissociative drugs (such as phenylcyclohexyl piperidine (PCP)) and serotonergic (classic hallucinogens) such as LSD. Both types of psychedelic drugs can cause hallucinations and feeling of sensation, moreover, dissociative drugs can make a person to fell out of control from their body or environment and makes them feel disconnected. Based on the source, psychedelic drugs have been categorized under natural and synthetic types.

These drugs have wide applications in the treatment of major depressive disorder, post-traumatic stress disorder, panic disorder, treatment-resistant depression and opiate addiction among others. Psychedelic drugs are also known by several other names such as lysergic acid derivative (LSD) which are also known as blotter, dots, sugar, acid, trips and window pane, ketamine are also known as vitamin K, bump, green, K/special K, purple and super acid, PCP are also known as angel/angel dust, boat/love boat, peace, killer weed, super grass and ozone.

Psychedelic Drugs Market Dynamics

Drivers

• Growing Acceptance of Psychedelic Drugs for Treating Depression

Psychedelics have achieved a large popularity within the last decade as are familiarly involved with human mental healing and treatment practices and have the power of mind-healing. The growing researchers and scientist are exploring psychedelic drugs therapeutic value and compounds which could be a new treatment option for people with depression. Continuous research and development in the psychedelic drugs has increased the acceptance of psychedelics medication. Psychedelic drugs promising outcomes have increased the usage of psychedelic drugs across the U.K. and other regions which leads to increasing demand for psychedelic drugs, hence these factors are expected to act as drivers for the growth of the market.

• Increasing Prevalence of Depression and Mental Disorders

Mental disorders (or mental illnesses) affects persons feeling, mood, thinking, and behaviour and can be long-lasting (chronic) or occasional. Depression and mental disorders have the ability to affect individual’s capacity by virtue of which they perform their everyday tasks. There are numerous dissimilar types of mental disorders. Depression and mental disorders have increased globally due to various factors including family history and genes, abuse or stress, biological factors, usage of alcohol or recreational drugs and many others.

Additionally, increasing consumption of illicit substances have increased depression and mental disorders. Thus, increasing prevalence of depression and mental disorders are increasing the demand for psychedelic drugs which is expected to act as drivers for the growth of the market.

Opportunity

• Increasing R&D Activities in Psychedelic Drugs

Psychedelic plants and fungi have been used in indigenous medicinal traditions for millennia. New psychedelic drugs development research has initiated by Albert Hofmann in 1938. He has synthesized the first lysergic acid diethylamide (LSD-25) and now recognized as the first person to ingest LSD after five years later. Hofmann was unaware of the significant effects and actions posed by that product. After a growing period of cultural and scientific exploration in the 1950s and 60s, psychedelic drug development research was slackened to a near halt. Increasing research and development expenditure in the psychedelic drugs is creating new opportunities in the market. Thus, increasing R&D activities in psychedelic drugs is acting as an opportunity for the growth of the market.

Also, the strategic initiatives taken by key market players will provide structural integrity and future opportunities for the psychedelic drugs market in the forecast period of 2025-2032.

Restraint/Challenge

• High Cost of Psychedelic Drugs

However, the high cost associated with psychedelic drugs will impede the growth rate of psychedelic drugs market. Additionally, stringent rules and regulations will further challenge the market in the forecast period mentioned above.

This psychedelic drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more information on psychedelic drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Europe Psychedelic Drugs Market Scope

Europe psychedelic drugs market is segmented into source, type, drugs, application, route of administration, end user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Source

• Synthetic
• Natural

Type

• Empathogens
• Dissociatives
• Others

Drugs

• Gamma-Hydroxybutyric Acid
• Ketamine
• Psilocybin
• Others

Application

• Narcolepsy
• Treatment Resistant Depression
• Major Depressive Disorder
• Opiate Addiction
• Post-Traumatic Stress Disorder
• Others

Route of Administration

• Oral
• Inhalation
• Injectable

End User

• Hospital
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospitals Pharmacy
• Retail Pharmacy
• Online Pharmacy

Psychedelic Drugs Market Regional Analysis    

The psychedelic drugs market is analyzed and market size insights and trends are provided by country, source, type, drugs, application, route of administration, end user and distribution channel as referenced above.

The countries covered in the psychedelic drugs report are U.K., Germany, Italy, France, Spain, Russia, Poland, Netherland, Hungary, Austria, Norway, Switzerland, Ireland, Belgium, Lithuania and Rest of Europe.

Germany is the country from Europe region dominates the psychedelic drugs market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to high awareness about mental disorders in the region and rapid research development is boosting the market.

The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of global brands and their challenges faced due to high competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.

Psychedelic Market Share

The psychedelic drugs market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on psychedelic drugs market.

Psychedelic Market Leaders Operating in the Market Are:

• Jazz Pharmaceuticals, Inc.
• Janssen Global Services, LLC (a subsidiary of Johnson & Johnson Services, Inc.)
• Hikma Pharmaceuticals PLC
• COMPASS
• Verrian, Pfizer Inc.
• F. Hoffmann-La Roche Ltd
• Avadel
• Celon Pharma SA.
• Cybin Corp.
• GH Research
• Entheon Biomedical Corp

Latest Developments in Psychedelic Market

• In August 2020, Janssen Pharmaceuticals, Inc. received approval for its Spravato nasal spray indicated for treatment of suicidal people. As approximately 11% to 12% of Americans suffers from major depressive disorder that led them to commit suicide, this approval provided these patients with a remarkable therapy and paved the way for the company to generate more revenue.

SKU-52363